Serum ferritin trajectories predict mortality risk in anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis: a longitudinal cohort study

European Respiratory Journal 2026

View at publisher
Authors: Yingfang Zhang, Xinyao Lai, Jie Li, Shiyu Wu, Xinxin Zhang, Chao Sun, Longyang Zhu, Linrong He, Yu Zuo, Wei Jiang, Guangtao Li, Xiaoming Shu
DOI: 10.1183/13993003.01802-2025
Cited by: 2
References: 14

Abstract

Extract Interstitial lung disease (ILD) associated with anti-melanoma differentiation-associated protein5 antibody positive (anti-MDA5+) dermatomyositis (DM) has a 6-month mortality rate of 33–66% despite aggressive immunosuppression, with rapidly progressive interstitial lung disease (RP-ILD) as the primary driver [1–4]. While elevated serum ferritin (SF) is an established prognostic biomarker in anti-MDA5+ DM, particularly among patients with RP-ILD, previous studies have relied on single-time-point measurements with inconsistent cutoffs due to heterogeneity [5–7], and comprehensive characterization of dynamic SF patterns during treatment in the real world is lacking. We hypothesized that SF trajectories could identify different subgroups with different mortality risks in patients with anti-MDA5+ DM.

Fields of Study & Subjects

Inflammatory Myopathies and Dermatomyositis Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Rheumatoid Arthritis Research and Therapies

Publication details

Journal / source
European Respiratory Journal
Publisher
European Respiratory Society (ERS)
Volume
67
Issue
4
Pages
2501802–2501802
Publication date
22 January 2026
Language
EN